Sreenivasa B P, Mohapatra J K, Pauszek S J, Koster M, Dhanya V C, Tamil Selvan R P, Hosamani M, Saravanan P, Basagoudanavar Suresh H, de Los Santos T, Venkataramanan R, Rodriguez L L, Grubman M J
ICAR-Indian Veterinary Research Institute, Hebbal, Bengaluru 560 024, Karnataka, India.
ICAR-Directorate of Foot and Mouth Disease, Mukteswar 263 138, Uttarakhand, India.
Vet Microbiol. 2017 May;203:196-201. doi: 10.1016/j.vetmic.2017.03.019. Epub 2017 Mar 18.
Recombinant adenovirus-5 vectored foot-and-mouth disease constructs (Ad5- FMD) were made for three Indian vaccine virus serotypes O, A and Asia 1. Constructs co-expressing foot-and- mouth disease virus (FMDV) capsid and viral 3C protease sequences, were evaluated for their ability to induce a neutralizing antibody response in indigenous cattle (Bos indicus). Purified Ad5-FMD viruses were inoculated in cattle as monovalent (5×10 pfu/animal) or trivalent (5×10 pfu/animal per serotype) vaccines. Animals vaccinated with monovalent Ad5-FMD vaccines were boosted 63days later with the same dose. After primary immunization, virus neutralization tests (VNT) showed seroconversion in 83, 67 and 33% of animals vaccinated with Ad5-FMD O, A and Asia 1, respectively. Booster immunization elicited seroconversion in all of the animals (100%) in the monovalent groups. When used in a trivalent form, the Ad5-FMD vaccine induced neutralizing antibodies in only 33, 50 and 16% of animals against serotypes O, A and Asia 1, respectively on primo-vaccination, and titers were significantly lower than when the same vectors were used in monovalent form. Neutralizing antibody titers differed by serotype for both Ad5-FMD monovalent and trivalent vaccines, with Asia 1 serotype inducing the lowest titers. Antibody response to Ad5 vector in immunized cattle was also assessed by VNT. It appeared that the vector immunity did not impact the recall responses to expressed FMDV antigens on booster immunization. In summary, the study suggested that the recombinant Ad5-FMD vaccine has a potential use in monovalent form, while its application in multivalent form is not currently encouraging.
针对印度口蹄疫三种疫苗病毒血清型O、A和亚洲1型,构建了重组腺病毒5型载体口蹄疫构建体(Ad5 - FMD)。构建体共表达口蹄疫病毒(FMDV)衣壳和病毒3C蛋白酶序列,评估其在本地牛(印度瘤牛)中诱导中和抗体反应的能力。将纯化的Ad5 - FMD病毒作为单价疫苗(5×10⁸ 个噬斑形成单位/动物)或三价疫苗(每种血清型5×10⁸ 个噬斑形成单位/动物)接种到牛体内。用单价Ad5 - FMD疫苗接种的动物在63天后用相同剂量进行加强免疫。初次免疫后,病毒中和试验(VNT)显示,接种Ad5 - FMD O、A和亚洲1型疫苗的动物中,血清阳转率分别为83%、67%和33%。加强免疫使单价组所有动物(100%)血清阳转。当以三价形式使用时,Ad5 - FMD疫苗在初次接种时分别仅在33%、50%和16%的动物中诱导出针对血清型O、A和亚洲1型的中和抗体,且滴度显著低于以单价形式使用相同载体时。Ad5 - FMD单价和三价疫苗的中和抗体滴度因血清型而异,亚洲1型血清型诱导的滴度最低。还通过VNT评估了免疫牛对Ad5载体的抗体反应。看来载体免疫并未影响加强免疫时对表达的FMDV抗原的回忆反应。总之,该研究表明重组Ad5 - FMD疫苗以单价形式有潜在用途,而其在多价形式中的应用目前并不乐观。